Skip to main content
Caplight Logo









Elkedonia

Elkedonia

Private
StrasbourgHealthcare & Life Scienceshttps://elkedonia.com/

Last Round

Seed

Jun 11, 2025

Total Funding Raised

$12.9M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Elkedonia is a drug discovery company that develops neuroplastogen therapies for treatment-resistant depression and other neuropsychiatric disorders.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Mental Health, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

neuroplastogen therapiesElk1 inhibitortreatment-resistant depressionTRDsmall molecule drug discoveryfirst-in-class therapypsychedelic alternativeketamine alternativenext-gen antidepressantspreclinical biotechpharma licensingprecision psychiatrycompanion biomarkersneuropsychiatric disorderspost-traumatic stress disorderPTSD

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elkedonia Comparables

Compare Elkedonia with similar companies based on industry and business-model similarity.

Elkedonia comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Delix Therapeutics
82%
Kasvu Therapeutics
81%
Transneural Therapeutics, Inc.
80%

Elkedonia Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJun 11, 2025

Key People

Founding team and executive leadership

Delphine Charvin

CEO and co-Founder

Founding Team

Sarah Delbaere

Chief Financial Officer

Executive Team

Elkedonia Investors

Notable investors and investment history

Elkedonia investors
InvestorRounds
Angelini VenturesSeed
Capital Grand EstSeed
CARMA FUNDSeed
SambrinvestSeed
Kurma PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 22, 2026

    Grew 43% QoQ, from 7 to 10 employees.

  • May 12, 2026

    Monthly visitors increased 41% MoM, from 663 to 937.

Elkedonia Filings

Explore SEC and related filing metadata, where available.

Elkedonia filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Elkedonia's valuation, stock price, and market status.

Is Elkedonia a public or private company?

Elkedonia is a private company.

What is the current stock price of Elkedonia?

Elkedonia is a private company with no public stock price. No recent secondary market data is available.

How much is Elkedonia worth (valuation)?

Valuation information for Elkedonia is not publicly available.

Can I buy Elkedonia stock?

Elkedonia shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Elkedonia's last funding round?

Funding round information for Elkedonia is not publicly available.

Who are the main investors in Elkedonia?

Investor information for Elkedonia is not publicly disclosed.

Will Elkedonia IPO soon?

No public IPO plans have been announced for Elkedonia.

How can I track Elkedonia secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Elkedonia's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStrasbourg
Employee Range8
Year Founded2025
Last FundingJun 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?